11. The compound according to claims 1-8 wherein R_5 is C(6)arylC(1-3)alkyl or C(3-6)cycloalkylC(1-3)alkyl.

12. The compound according to claim 11 wherein R_5 is benzyl.

13. The compound according to claims 1-12 wherein R_6-R_{10} are H with the proviso that one of the groups R_7, R_8 or R_9 is the sulfonyl group with R_1.

14. The compound according to claim 13 wherein R_8 is the sulfonyl group with R_1.

15. The compound according to claims 1-12 wherein R_8 is the sulfonyl group with R_1, and wherein R_{10} is methyl, and the remaining R_6, R_7 and R_9 are H.

16. The compound according to claims 1-15 wherein A_{11}-A_{14} are CR_{11}, CR_{12}, CR_{13} and CR_{14}, respectively.

17. The compound according to claims 1-15 wherein either:
A_{11} is nitrogen and A_{12}-A_{14} are CR_{12}, CR_{13} and CR_{14}, respectively; or,
A_{12} is nitrogen and A_{11}, A_{13} and A_{14} are CR_{11}, CR_{13} and CR_{14}, respectively.

18. The compound according to claims 1-17 wherein R_{11}-R_{14} are independently H, halogen, methyl or methoxy.

19. The compound according to claim 18 wherein R_{11}-R_{14} is H.

20. The compound according to claims 1-19 wherein R_{15} is CF_3 and R_{16} is H, C(1-6)alkyl, C(3-6)cycloalkyl or C(3-6)cycloalkylC(1-3)alkyl.

21. The compound according to claim 20 wherein R_{15} is CF_3 and R_{16} is CF_3, propyl, isopropyl, 2-methylpropyl, 2,2-dimethylpropyl, cyclopropyl, cyclopentyl or cyclohexylmethyl.

22. The compound according to claim 21 wherein both R_{15} and R_{16} are CF_3.

23. The compound selected from claim 1 which is selected from the group of:

2-(4-((cyclopropylmethyl)sulfonyl)phenyl)-*N*-(4-(2-hydroxypropan-2-yl)phenyl)acetamide;
2-(4-((cyclopropylmethyl)sulfonyl)phenyl)-*N*-(4-(1,1,1-trifluoro-2-hydroxy-5-methylhexan-2-yl)phenyl)acetamide;
2-(4-(*N*-cyclopropylsulfamoyl)phenyl)-*N*-(5-fluoro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-2-methoxyphenyl)acetamide;
2-(4-((cyclopropylmethyl)sulfonyl)phenyl)-*N*-(4-(dicyclopropyl(hydroxy)methyl)phenyl)acetamide;
2-(4-((cyclopropylmethyl)sulfonyl)phenyl)-*N*-(5-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)pyridin-2-yl)acetamide;
2-(4-((cyclopropylmethyl)sulfonyl)phenyl)-*N*-(4-(1,1,1-trifluoro-2-hydroxy-6-methylheptan-2-yl)phenyl)acetamide;
2-(4-((cyclopropylmethyl)sulfonyl)phenyl)-*N*-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)propanamide;
2-(4-((cyclopropylmethyl)sulfonyl)phenyl)-*N*-(6-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)pyridin-3-yl)acetamide;
2-(4-(ethylsulfonyl)phenyl)-*N*-(6-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)pyridin-3-yl)acetamide;
2-(4-(ethylsulfonyl)phenyl)-*N*-(4-(1,1,1,3,3,3-hexafluoro-2-(2,2,2-trifluoroethoxy)propan-2-yl)phenyl)acetamide;
2-(4-((cyclopropylmethyl)sulfonyl)phenyl)-*N*-(4-(1,1,1,3,3,3-hexafluoro-2-(2,2,2-trifluoroethoxy)propan-2-yl)phenyl)acetamide and
2-(4-((cyclopropylmethyl)sulfonyl)phenyl)-*N*-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-2-hydroxyacetamide.

24. The compound according to claim 23 which is 2-(4-((cyclopropylmethyl)sulfonyl)phenyl)-*N*-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxy propan-2-yl)phenyl)acetamide.
25. The compound according to anyone of claims 1 to 24 or a pharmaceutically acceptable salt thereof for use in therapy.
26. The compound according to anyone of claims 1 to 24 or a pharmaceutically acceptable salt thereof for use in the treatment of RORγ-mediated diseases or conditions.
27. A pharmaceutical composition which comprises a compound of Formula **I** according to any of claims 1 to 24 or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.